Up 193.5% Year-on-Year
OscoTek announced on February 27 that it recorded consolidated sales of 99.83866 billion won and operating profit of 52.08329 billion won in 2025, marking a turnaround to profitability. This represents a 193.5% increase compared to the previous year's sales of 34.0076 billion won.
According to the company, the improved results were largely due to milestone payments and royalty income related to the lung cancer treatment "Lazertinib." The combination therapy of Leclaza and Rybrevant received approval in Japan and China, leading to commercialization-stage technology fees, while royalty revenue also grew as prescriptions expanded.
Sales also reflected the achievement of a technology transfer for the Alzheimer's disease treatment candidate "ADEL-Y01." OscoTek had previously transferred the ADEL-Y01 candidate to global pharmaceutical company Sanofi and received an upfront payment.
OscoTek plans to enhance the efficiency of research and development and business operations by establishing a "dual hub" system with its U.S. subsidiary, Genosco. Over the mid- to long-term, the company aims to foster anti-resistance cancer drugs that block the occurrence of resistance as its core pipeline.
Yoon Taeyoung, CEO of OscoTek, stated, "We will continue to expand the development of innovative new drugs based on the achievements of our technology transfers. We also intend to improve development efficiency of our existing pipeline through external partnerships."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
